Effective April 15, patients may bring one visitor to an appointment.
Learn more about this and other COVID-19 related updates

Clinical Trials & Research

View Open Trials

Anal

  • Ph3 Carbo/Pac NCMGA00012 MSCC

    A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)


Bladder

  • PH 2 Enfortumab in Urothelial Pts

    A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)


  • Pembro in combo CRT vs CRT alnoe MIBC

    Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)


  • Ph3 Infigratinib UC w/ FGFR3 Alt

    QBGJ398-302: Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF302)


  • Ph3 FGFR erdafitinib urothelial

    (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)


  • Biomarker Advcd Uro Cancer and FGFR Aber

    Biomarker Study to Identify Subjects with Advanced Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations (42756493BLC0002)


  • Sitravatinib + Nivo Adv/Met Urothelial

    A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)


  • NeoAdj Chemo +/- Nivo/IDO1inh MIBC

    A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer (CA017078)


Breast

  • Ph1/2 Ibrutinib+Tras HER2 amp/MBC

    Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer


  • Ph 3 BYL719 + nabpax TNBC PIK3CA

    EPIK-B3: A phase III, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)


  • EndoPredict (EXET) Breast Registry study

    EndoPredict® Extended Endocrine Trial (EXET): A prospective registry to evaluate the impact of EndoPredict® in decisions regarding extended endocrine treatment (ONC-010)


  • Ph2 m7824 triple neg BC

    (MS200647_0020) A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with HMGA2-expressing Triple Negative Breast Cancer


  • Ph 3 Chemo+Atez/Placbo TNBC

    A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo(NSABP B-59/GBG 96-GeparDouze).


  • Ph 3 Tuca/Placbo + T-DM1 HER2+

    STAR: Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)


  • FLEX Registry: Evaluate New Gene Express

    MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)


Cholangiocarcinoma

  • Infigratinib vs Gem/Cis Cholangio

    A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)


Head and Neck

  • Ph3 GC4419 Oral Mucositis H&N

    ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer (GTI-4419-301)


Leukemia

  • PH3 Ven+G vs FCR/BR in Fit untreated CLL

    A PROSPECTIVE, OPEN-LABEL, MULTICENTER RANDOMIZED PHASE III TRIAL TO COMPARE THE EFFICACY AND SAFETY OF A COMBINED REGIMEN OF OBINUTUZUMAB AND VENETOCLAX VERSUS FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR)/ BENDAMUSTINE AND RITUXIMAB (BR) IN FIT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITHOUT DEL (17P) OR TP53 MUTATION (CO41685)


Lung (Non Small Cell)

  • Ph1/2 MRTX849 Solids KRAS G12C

    A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)


  • KEAP1/NRF2 NSCLC

    CX-839-014 "KEAPSAKE": A Phase 2, Randomized, Multicenter, Double-blind, Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)


  • PH3 pral(Blu-667) RET-fusion mNSCLC

    A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)


  • PH3 Osi +/- Platinum Chemo/Pem NSCLC

    A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2) (D5169C00001)


  • PH3 AMG 510 vs Doce a/mNSCLC

    20190009: A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects with Mutated KRAS p.G12C


  • PH3 Atez Tira Dura Sg 3 NSCLC

    GO41854: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03)


  • Ph 3 Durv vs. plbo SBRT NSCLC (PAC 4)

    D9103C00001: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)


  • Ph2 IMMU-132 met Solid Tumors

    A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors (IMMU-132-11)


  • Ph3 ALK+ mNSCLC (Brigatinib-3001)

    Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)


  • BIODESIX

    Clinical Effectiveness Assessment of VeriStrat© Testing and Validation of Immunotherapy Tests in NSCLC Subjects (INSIGHT)


Lymphomas

  • Ph2 A+AVD +G-CSF or AOAD in CHL

    SGN35-027: Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects


  • PH3 R-CHOP +/- Acalab Tx Naive DLBCL

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects < or = 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma (ACE-LY-312/ D8227C00001)


  • Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

    A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)


  • BV in older pts w/1L cHL or PTCL

    (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy


Prostate

  • Ph3 Nirap+Abirat+Pred mCRPC

    A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)


  • PH3 Nirap Abira HRR mCSPC

    A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)


  • Ph3 Nivo +/- Doce mPC 7DX

    A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CA209-7DX)


  • Ph 2 Nivo+Ipil, Ipil mono or Caba CR mPC

    A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer (CA209-650)


  • Biomarker DNA Defect Men Prostate

    Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (64091742PCR0002)


Renal

  • MK-6482 Advanced Renal Cell Carcinoma

    MK6482-013: Phase 2 Study of MK-6482 in Participants with Advanced Renal Cell Carcinoma


  • PH3 Ate +Cabo Renal Carcinoma

    A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT (WO41994)


  • GU-102 Ph I/II Nivo + axitinib RCC

    Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma


PH3 Ate +Cabo Renal Carcinoma

  • PH3 Ate +Cabo Renal Carcinoma

    A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB GIVEN IN COMBINATION WITH CABOZANTINIB VERSUS CABOZANTINIB ALONE IN PATIENTS WITH INOPERABLE, LOCALLY ADVANCED, OR METASTATIC RENAL CELL CARCINOMA WHO EXPERIENCED RADIOGRAPHIC TUMOR PROGRESSION DURING OR AFTER IMMUNE CHECKPOINT INHIBITOR TREATMENT (WO41994)


Solid Tumors

  • Ph2 Basket Tucat+Tras ST HER2 Alt

    A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (SGNTUC-019)


  • Ph2 Bren Vedo + Pembro ST prior PD-1

    A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)


  • Ph2 Erdafitinib FGFR Solid Tumors

    A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)


  • Ph 1 CPI-006+444/Pembro ST/NHL

    A PHASE 1/1B MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS (CPI-006-001)


  • Ph2 Pemigatinib Solids FGFR

    (INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)


  • Ph1/2 BLU667 thy, NSCLC, Sol tum

    A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (BLU-667-1101)


Basal Cell Carcinoma

  • Ph1 CX-4945 Basal Cell Carcinoma

    A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)


Colorectal

  • PH2 Tuca+ Tras HER2+ CC

    MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617, SGNTUC-017)


Multiple Myeloma

  • PH3 Dara/Len vs Len NDMM

    A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)


Myelofibrosis

  • Ph3 Navi Ruxo Myelofibrosis

    M16-191: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)


  • PH3 Pacritinib vs MD choice in MF

    A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50,000/µL) (PAC203)